Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline.
Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline.
复制标题
强迫症。
DOI：
10.1001/archpsyc.1983.04390010015002
复制
发表时间：
1983
影响因子：
--
通讯作者：
M. Linnoila
中科院分区：
文献类型：
--
作者：
T. Insel;D. Murphy;R. Cohen;I. Alterman;C. Kilts;M. Linnoila
对符合 DSM-III 标准且患病至少一年的强迫症患者进行了三环类抗抑郁药盐酸氯米帕明和单胺氧化酶抑制剂盐酸氯吉林的双盲、随机、交叉比较。在交叉研究之前使用安慰剂治疗四个星期后，没有明显的改善。氯米帕明治疗四周和六周后，强迫症、焦虑和抑郁指标均显着改善。对氯米帕明的抗强迫反应并不取决于抑郁症的存在。改善与氯米帕明的血浆浓度相关，但与其任何代谢物的血浆浓度无关。尽管个别患者的病情确实对该药物有反应，但整个接受氯吉林治疗的组没有明显的改善。
Patients with obsessive-compulsive disorder who met DSM-III criteria and who had been ill for at least one year were studied in a double-blind, randomized, crossover comparison of the tricyclic antidepressant clomipramine hydrochloride and the monoamine oxidase inhibitor clorgyline hydrochloride. No significant improvement was evident after four weeks of treatment with placebo prior to the crossover study. Treatment with clomipramine was associated with significant improvement after both four and six weeks in measures of obsessions, anxiety, and depression. Antiobsessional responses to clomipramine did not depend on presence of depression. Improvement was correlated with plasma concentrations of clomipramine, but not with the plasma concentrations of any of its metabolites. No significant improvement was evident for the entire group with clorgyline treatment, although the conditions of individual patients did respond to the drug.